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Abstract Title: 
Differential expression and translation of adenosine receptor agonists in human detrusor from 
stable and overactive bladders and its consequence in regulating detrusor contractility. 
 
Abstract Text: 
Hypothesis / aims of study 
Adenosine is generated from the breakdown of the excitatory neurotransmitter ATP and is an 
agonist for P1 receptors of which there are four subtypes (A1, A2A, A2B, A3).  It suppresses 
detrusor contractions in animal tissue thus offering a potential negative feedback pathway to 
regulate muscle contractility.  We tested the hypothesis that adenosine receptor agonists 
modulate contraction differently in human detrusor from stable and overactive bladders and is 
reflected in differential adenosine receptor gene expression and translation. 
 
Study design, materials and methods 
Detrusor specimens were obtained from patients undergoing cystectomy/augmentation 
ileocystoplasty, with local ethical committee approval and informed patient consent.  Patients 
were grouped into two sets: symptomatically stable bladders; or those with urodynamically-
proven neuropathic detrusor overactivity (NDO).  Muscle strips, with the mucosa removed, 
were superfused with Tyrode’s solution (37°C, 24 mM NaHCO3, 5% CO2).  Nerve-mediated 
contractions were elicited by field-stimulation (0.1 ms pulses, 3s trains, 20 Hz) and were 
completely abolished by 1 µM tetrodotoxin.  Direct-muscle stimulated contractures were 
generated by addition of 1 µM carbachol to the superfusate in unstimulated preparations.  
Responses were measured during exposure to P1 receptor agonists and antagonists and 
calcualted as a percentage of the mean control response before and after the intervention.  
Portions of the biopsy were also saved in liquid N2 for extraction of total RNA and protein. 
RNA was extracted, the concentrations in each sample measured, and amplified by RT-PCR 
against primer sequences for the four receptor subtypes (Human Genome Project website; 
http://www.genome.gov/10001772); GAPDH-3 was the housekeeping gene.  Table 1 shows 
the primers used.  Total protein was extracted from other samples and analysed by Western 
blotting using polyclonal antibodies to the four receptor subtypes (Alpha Diagnostic 
Chemicals, Cambridge, U.K.).  Bands were analysed by densiometric analysis and 
normalised to those probed GAPDH-3 protein antibodies.  Data are medians (25%,75% 
interquartiles] and differences between samples from overactive and stable bladders were 
tested using Wilcoxon’s rank scoring test, the null hypothesis was rejected at p<0.05. 
 
Table 1.  Primers used for RT-PCR of adenosine-receptor mRNA. 
Primer Sense Antisense 
A1 5’-gccacagacctacttccaca-3’ 5’-ccttctcgaactcacacttg-3’ 
A2A 5’-aacctgcagaacgtcaccaa-3’ 5’-gtcaccaagccattgtaccg-3’ 
A2B 5’-gatcattgctgtcctctgg-3’ 5’-tcctcgagtggtccatcag-3’ 
A3 5’-accactcaaagaagaatatg-3’ 5’-acttagctgtcttgaactcc-3’ 
GAPDH-3 5’-gagtcaacggatttggtcgt-3’ 5’-ttgaggtcaatgaaggggtc-3’ 
 
Results 
Nerve-mediated contractions were of similar magnitude in samples from patients with stable 
bladders and NDO (32.0 [19.7, 45.9] and 33.5 [19.6, 53.9] mN.mm-2 respectively, n=19,19).  
However atropine-resistance (percentage of contracrtions after 1 µM atropine) was greater in 
the NDO preparations (2.9 [2.0, 4.6] and 36.4 [15.5, 44.4]% respectively). 
 
Table 2 shows the effect of adenosine, as well as the A1-selective agonist CPA (N6-
cyclopentyladenosine, 10 µM) and the A2A-selective agonist CGS-21680 (3-[4-[2-[ [6-amino-
9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl] 
propanoic acid, 10 µM).  The A3-selective agonist IB-MECA (chloro-N6-(3-iodobenzyl)-
adenosine-5′-N-methyluronamide, 10 µM) was also used but generated no specific changes 
in contractile responses, therefore the results are not reported here. 
 
Table 2. Effect of adenosine, CPA and CGS-21680 on nerve-mediated and carbachol-
generated contractions in human detrusor from stable and NDO bladders.  Contraction, % 
control. * p<0.05 compared to control (100%); § p<0.05 NDO vs control 
 Adenosine (1 mM) CPA (10 µM) CGS-21680 (10 µM) 
n-m contraction (%), 
stable 
57.3 [54.0, 67.2] * 
(n=16) 
94.8 [94.7,97.1] * 
(n=6) 
94.7 [94.6,97.3] * 
(n=6) 
n-m contraction (%), 
NDO 
43.6 [39.9, 47.8] *§ 
(n=10) 
47.3 [42.4, 58.2] *§ 
(n=7) 
102.0 [97,4,104.7] 
(n=7) 
Carbachol contraction 
(%), stable 
41.4 [36.9, 44.6] * 
(n=9) 
88.9 [88.3, 94.3] * 
(n=9) 
98.7 [97.4,100.0]  
n=9 
Carbachol contraction 
(%), NDO 
52.3 [43.5, 72.1] *§ 
(n=6) 
95.5 [94.3, 99.7] § 
(n=6) 
98.0 [97.3, 99.6] 
n=6 
 
Adenosine reduced nerve-mediated contractions in both groups but the effect was 
significantly greater in the NDO group.  By contrast, adenosine exerted a greater depressant 
action on the carbachol contracture in stable bladder samples compared to the NDO group. 
 
CPA  caused a small reduction of the nerve-mediated contraction, but eth effect was 
significantly greater in the NDO preparations.  Again, by contrast, with carbachol contractions 
CPA had a small depressant effect in stable bladder samles, but none on NDO preparations. 
 
CGS-21680 had a small significant effect on nerve-mediated contractions from stable bladder 
samples, but had no other effects. 
 
RT-PCR results showed that A1-receptor expression (relative to GAPDH-3 expression) was 
similar in stable and NDO bladder groups (0.068 [0.054, 0.099] and 0.054 [0.042, 0.067], 
respectively; n=6,7).  However, A2A receptor expression was grealy reduced in the NDO 
samples (0.193 [0.157, 0.218] and 0.036 [0.034, 0.042], respectively; n=6,7; p<0.05).  No 
differnences in A2B and A3 expression were noted between the two groups. 
 
Western blot analysis did not record any bands to A1 protein in any sample.  However, the 
density of A2A bands were greatly reduced in NDO samples compared to those from stable 
bladders; to 3.8 [1.06, 7.9] %. 
 
Interpretation of results 
Adenosine depressed nerve-mediated and agonist-induced contractions in human detrusor 
from stable and NDO bladders, but there were significant mechanistic differences in the mode 
of action between the two groups.  We have shown previously in guinea-pig detrusor (Y 
Ikeda, CH Fry unpublished data) that A1 agonists act a presynaptic site and A2/3 receptors 
on the muscle.  The large effect of the A1-selective agonist, CPA on depressing nerve-
mediated contractions in NDO samples implies adenosine acts at a presynaptic site.  By 
contrast the greater effect of adenosine on carbachol contractions in stable bladder samples, 
and the small effect of CPA implies it acts more on the muscle cell and much less at a 
presynaptic site.  The relative lack of effect of A2A and A3 agonists implies that adenosine 
does not act through these receptors on detrusor muscle from stable bladders.  A2B agonists 
were not used the non-availability of selective agents.  The greater incidence of atropine-
resistant contractions in NDO bladder samples permits the postulation that adenosine has a 
selective presynaptic effect on suppressing non-cholinergic transmitters.  The significant loss 
of A2A receptor expression and translation in NDO bladders should not hinder its ability to act 
as a presynaptic inhibitor. 
 
Concluding message 
The negative intropic effect of adenosine on human detrusor muscle is mediated by different 
mechanisms in tissue from  overactive bladders and stable bladders.  This offers a route to 
develop agents that can selectively modulate contractile function in the overactive bladder. 
